Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

Retina Institute of Hawaii

Status: Completed

Conditions: Wet AMD

Treatments: Drug: Lucentis

Study type: Observational

Funder types: Other

Identifiers

NCT00804934

F4421S

Details and patient eligibility

About

The purpose of this study is to determine whether people who have received intermittent anti-VEGF therapy have an improvement in vision after being switched to monthly injections of Lucentis.

Full description

To determine mean change in visual acuity at 6 and 12 months

Enrollment: 100 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Ability to provide written informed consent and comply with study assessments for the full duration of the study
• Age greater then and equal 50 years
• Patients with active neovascular AMD
• Received at least 3 treatments with anti-VEGF therapy (bevacizumab or pegaptanib or ranibizumab) in the last 24 months
• If the patient has bilateral disease and qualifies for the study, both eyes may be included

Exclusion criteria

• Subjects who meet any of the following criteria will be excluded from this study:
• Pregnancy or lactation
• Premenopausal women not using adequate contraception.
• Participation in another simultaneous medical investigation

Trial design

100 participants in 1 patient group

0

Treatment:

Drug: Lucentis